CARL ZEISS MEDI UNSP/ADR - CZMWY STOCK NEWS

ZEISS Medical Technology is showcasing new digital enhancements and surgical solutions at the American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago. Key highlights include:

• Introduction of ZEISS VisioGen, an AI-driven solution for enhancing refractive patient communication and streamlining clinic operations
• Celebration of 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro lenticule extraction solutions
• Marking 25 years of leadership in optical biometry with ZEISS IOLMaster biometers
• Demonstration of the FDA-cleared ZEISS MICOR 700, the first hand-held lens removal device with ultrasound-free operation
• Expansion of the ZEISS Retina Workflow to include advanced vitreoretinal surgical solutions from DORC
• FDA clearance for next-generation ZEISS VISULAS combi and green therapeutic lasers

These innovations aim to advance clinical workflows and support personalized care across cataract, corneal refractive, retina, and glaucoma treatments.

ZEISS Medical Technology has launched the KINEVO® 900 S, its latest Robotic Visualization System® for neurosurgery, at the Congress of Neurological Surgeons in Houston. This system, an evolution of the successful ZEISS KINEVO 900 platform, offers enhanced digital visualization, collaborative assistant functions, and connected intelligence for complex surgical procedures.

Key features include:

• 4K 3D digital image quality with a new DepthPro Mode
• Hybrid visualization concept for uninterrupted workflow
• Cobotic assistant with AI-powered functions like AutoCenter
• Connected digital solutions for data management and collaboration
• ZEISS OPTIME complete+ service plan with 98% uptime guarantee

The KINEVO 900 S will be gradually available in all existing markets following its launch.

ZEISS Medical Technology has announced the broad U.S. distribution of the MICOR® 700, the first hand-held ultrasound-free lens removal device. This revolutionary device uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to broaden surgeons' intraocular working space, minimize risk to surrounding eye structures, and increase operating room efficiency.

Key features of the ZEISS MICOR 700 include:

• Patented crystalline lens extraction technology
• Blunt and rounded tip design
• Single-use "plug & play" system with minimal O.R. footprint
• Less thermal energy delivery than phaco
• Cavitation-free lens removal
• Disposable fluidics system to mitigate cross-contamination risk

The device is FDA approved and commercially available in the U.S. It will be demonstrated at the American Academy of Ophthalmology (AAO) conference from Oct. 19 – 21, 2024, in Chicago.

ZEISS Medical Technology is showcasing innovative solutions for retinal patient care at EURETINA 2024. Key highlights include:

• The ARTEVO 850 3D digital visualization system for ophthalmic surgery, offering customizable 3D visualization and integrated intraoperative OCT
• Single-use Lenses for ZEISS RESIGHT fundus viewing system
• The EVA NEXUS surgical system from DORC for vitreoretinal and cataract procedures
• CIRRUS PathFinder, an AI-based tool for efficient OCT data review
• A new spatial computing app for Apple Vision Pro, allowing surgeons to review 2D/3D surgery videos and patient information

These innovations aim to improve diagnosis, treatment efficiency, and patient outcomes in retinal care.

ZEISS Medical Technology is showcasing its latest innovations at the ESCRS conference, highlighting advancements in cataract and corneal refractive workflows. Key developments include:

1. ZEISS SMILE pro for hyperopia treatment in CE markets, with over 10 million eyes treated using ZEISS SMILE technology.

2. Introduction of advanced optical and digital ophthalmic microscopes: ZEISS ARTEVO 750 and ZEISS ARTEVO 850.

3. New clinical results for the AT ELANA 841P trifocal IOL.

4. AI advancements: ZEISS AI IOL Calculator (CE-marked) and CIRRUS PathFinder (pending CE mark) for improved pre-operative patient care.

5. ZEISS Surgery Optimizer with AI-based video segmentation for post-surgery analysis.

These innovations aim to enhance surgical workflows, improve patient outcomes, and pave the way for more personalized care in ophthalmology.

On May 30, 2024, ZEISS Medical Technology announced enhancements to its CIRRUS 6000 OCT device. These upgrades include the largest OCT reference database in the U.S. market, featuring data from 870 healthy eyes, and advanced cybersecurity features. Recently FDA-cleared, the CIRRUS 6000 aims to facilitate data-driven patient care and improve clinical workflows for ophthalmologists. Key features include high-speed imaging, a wide field of view, and advanced visualization tools for retina, glaucoma, and anterior segment analysis. The device also ensures secure, seamless data transfer from previous CIRRUS models, emphasizing efficiency and compliance in clinical settings.

ZEISS completes acquisition of D.O.R.C., enhancing its ophthalmic portfolio and digital workflow solutions. The integration aims to drive innovation, expand market presence, and offer advanced technologies to ophthalmologists worldwide.

ZEISS introduces new 3D visualization technology and surgical innovations at ASCRS 2024, showcasing the ARTEVO 850 and 750 microscopes, along with the VISUMAX 800 for refractive surgery. The company aims to redefine the ophthalmic market with advanced visualization solutions and workflow enhancements.

Carl Zeiss Meditec AG (ZEISS) introduces the VISUMAX® 800 with SMILE® pro software, approved by the FDA for treating nearsightedness, with or without astigmatism, offering faster treatment, greater flexibility, and significant workflow enhancements. The latest generation of femtosecond lasers from ZEISS enters the U.S. market with over 8 million eyes treated globally, reflecting strong adoption in Asia and Europe. Surgeons can now offer the latest refractive technology to expand their business and provide excellent outcomes for patients. The system enables faster treatment, greater flexibility, and workflow enhancements, providing substantial market opportunities for U.S. surgeons.